---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-295566"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:41:23.536486+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience reports 26% ORR in TSC1 arm, 11% in TSC2 arm from PRECISION1 interim analysis

## Summary
- TSC1 arm (n=22): 26% ORR (5 PRs, 4 confirmed), 42% clinical benefit rate, median 3 prior therapies.
- TSC2 arm (n=18): 11% ORR (2 PRs, 1 confirmed), 28% clinical benefit rate, 50% had ≥5 prior lines.
- No new safety signals; one grade 2 pneumonitis resolved; safety consistent with mTOR class.
- 80 patients now enrolled; two-thirds interim analysis expected 3Q 2024; trial completion by end 2024.

## SEC filing metadata
- accession: 0001193125-23-295566
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312523295566/0001193125-23-295566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312523295566/d572047d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-295566
- JSON: https://secwatch.observer/filing/0001193125-23-295566.json
- Plain text: https://secwatch.observer/filing/0001193125-23-295566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.